[Form 4] Vivani Medical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 Filing Details: Aaron Mendelsohn, Director of Vivani Medical (VANI), received a non-qualified stock option grant on June 24, 2025, as part of the company's Non-Employee Director Compensation Policy.

Key Transaction Details:

• Granted 35,135 stock options to purchase common stock
• Exercise price set at $1.27 per share
• Options expire on June 23, 2035
• Vesting occurs on earlier of: first grant anniversary or next annual stockholder meeting

The filing was signed by Adam Mendelsohn as attorney-in-fact on June 26, 2025. This transaction represents standard annual director compensation and indicates continued board engagement. The vesting structure aligns with typical corporate governance practices for director equity compensation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mendelsohn Aaron

(Last) (First) (Middle)

C/O VIVANI MEDICAL, INC.

1350 S. LOOP ROAD

(Street)

ALAMEDA CA 94502

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vivani Medical, Inc. [ VANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$1.27	06/24/2025		A		35,135		(1)(2)	06/23/2035	Common Stock	35,135(2)	$1.27(2)	35,135(2)	D

Explanation of Responses:

1. Annual grant awarded pursuant to the Issuer's Non-Employee Director Compensation Policy.

2. The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Adam Mendelsohn, Attorney-in-fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did VANI director Aaron Mendelsohn receive on June 24, 2025?

Aaron Mendelsohn received 35,135 non-qualified stock options with an exercise price of $1.27 per share. These options were granted as part of VANI's Non-Employee Director Compensation Policy.

When do Aaron Mendelsohn's VANI stock options vest?

The stock options vest in full on the earlier of either (i) June 24, 2026 (the first anniversary of the grant) or (ii) VANI's next annual meeting of stockholders, subject to Mendelsohn's continued service through such date.

What is the expiration date for VANI director Mendelsohn's stock options?

The non-qualified stock options expire on June 23, 2035, ten years after the grant date.

Who filed this Form 4 for VANI and what is their role?

The Form 4 was filed for Aaron Mendelsohn, who serves as a Director of Vivani Medical, Inc. (VANI). The form was signed by Adam Mendelsohn as attorney-in-fact on June 26, 2025.

What is the total value of VANI stock options granted to Mendelsohn?

The grant consisted of 35,135 non-qualified stock options with an exercise price of $1.27 per share, representing the right to purchase 35,135 shares of VANI common stock upon exercise.